Treatment of cognitive impairment with PDE4 inhibitor

Patent metadata

Field	Value
Publication number	US-10357486-B2
Application number	US-201414460905-A
Country	US
Kind code	B2
Filing date	Aug 15, 2014
Priority date	Aug 16, 2013
Publication date	Jul 23, 2019
Grant date	Jul 23, 2019

Abstract

This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast.

First claim

The invention claimed is:

1. A method of treating mild cognitive impairment in a human in need of such treatment, the method comprising:
administering to the human suffering from mild cognitive impairment a phosphodiesterase 4 inhibitor selected from the group consisting of roflumilast, a pharmaceutically acceptable salt of roflumilast, roflumilast-N-oxide and a pharmaceutically acceptable salt of roflumilast-N-oxide,
wherein the phosphodiesterase 4 inhibitor is administered to the human at a daily dose consisting of between 50 mcg and 100 mcg.

2. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is selected from the group consisting of roflumilast and a pharmaceutically acceptable salt of roflumilast.

3. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is selected from the group consisting of roflumilast-N-oxide and a pharmaceutically acceptable salt of roflumilast-N-oxide.

4. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is roflumilast.

5. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is roflumilast-N-oxide.

6. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is administered at a daily dose of 50 mcg or 100 mcg.

7. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is roflumilast and wherein the phosphodiesterase 4 inhibitor is administered at a daily dose of between 50 mcg and 100 mcg.

Assignees

• Univ Maastricht

Inventors

• Prickaerts Jos
• Van Duinen Marlies
• Sambeth Anke
• Blokland Arjan

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/44 Primary

  Non condensed pyridines; Hydrogenated derivatives thereof · CPC title

• A61K9/2018

  Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates · CPC title